Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility | MicrobiomeTrials← Back to trialsNCT04244877
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
WITHDRAWNPHASE3INTERVENTIONAL
Trial Details
Start: 2021-09-15Est. Completion: 2023-05-01
Enrollment target: 0 participants Other microbiome trials you might be interested in
Intrahepatic Cholangiocarcinoma (Icc)
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…
Guangzhou, ChinaEst. completion Jan 2030
Cystic FibrosisImmunologic Deficiency SyndromeTurner SyndromeCongenital Hepatic FibrosisIdiopathic Non-Cirrhotic Portal Hypertension
Background:
\- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood …
Bethesda, United StatesEst. completion Sep 4, 2029
Hematopoietic Stem Cell Transplant
Background:
Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But m…
Bethesda, United StatesEst. completion Jun 30, 2031